Leerink Partnrs Issues Positive Outlook for TRVI Earnings

Trevi Therapeutics, Inc. (NASDAQ:TRVI) – Equities researchers at Leerink Partnrs raised their Q1 2025 EPS estimates for shares of Trevi Therapeutics in a research report issued to clients and investors on Tuesday, March 18th. Leerink Partnrs analyst F. Khurshid now anticipates that the company will post earnings of ($0.10) per share for the quarter, up from their previous estimate of ($0.13). The consensus estimate for Trevi Therapeutics’ current full-year earnings is ($0.49) per share. Leerink Partnrs also issued estimates for Trevi Therapeutics’ Q2 2025 earnings at ($0.11) EPS, Q4 2025 earnings at ($0.12) EPS, FY2025 earnings at ($0.45) EPS and FY2026 earnings at ($0.45) EPS.

Other research analysts also recently issued research reports about the stock. HC Wainwright reaffirmed a “buy” rating and issued a $12.50 price objective on shares of Trevi Therapeutics in a research report on Wednesday. Needham & Company LLC cut their price objective on shares of Trevi Therapeutics from $25.00 to $24.00 and set a “buy” rating on the stock in a research report on Wednesday. Oppenheimer lifted their price objective on shares of Trevi Therapeutics from $12.00 to $20.00 and gave the stock an “outperform” rating in a research report on Tuesday, March 11th. B. Riley reaffirmed a “buy” rating and issued a $20.00 price objective (up previously from $11.00) on shares of Trevi Therapeutics in a research report on Wednesday. Finally, Raymond James raised shares of Trevi Therapeutics from an “outperform” rating to a “strong-buy” rating and lifted their price objective for the stock from $9.00 to $29.00 in a research report on Monday, March 10th. Seven investment analysts have rated the stock with a buy rating and three have given a strong buy rating to the stock. Based on data from MarketBeat, Trevi Therapeutics presently has an average rating of “Buy” and an average target price of $17.56.

Trevi Therapeutics Stock Performance

NASDAQ:TRVI opened at $6.61 on Friday. Trevi Therapeutics has a one year low of $2.30 and a one year high of $7.39. The firm has a market cap of $508.08 million, a P/E ratio of -15.02 and a beta of 0.90. The firm has a 50-day simple moving average of $4.55 and a 200-day simple moving average of $3.73.

Trevi Therapeutics (NASDAQ:TRVI) last posted its quarterly earnings results on Tuesday, March 18th. The company reported ($0.11) EPS for the quarter, beating the consensus estimate of ($0.12) by $0.01.

Institutional Trading of Trevi Therapeutics

Several large investors have recently made changes to their positions in TRVI. GSA Capital Partners LLP purchased a new stake in shares of Trevi Therapeutics in the 3rd quarter valued at $409,000. Oppenheimer & Co. Inc. boosted its holdings in shares of Trevi Therapeutics by 34.7% in the 3rd quarter. Oppenheimer & Co. Inc. now owns 81,947 shares of the company’s stock valued at $274,000 after acquiring an additional 21,128 shares during the last quarter. Intech Investment Management LLC purchased a new stake in shares of Trevi Therapeutics in the 3rd quarter valued at $63,000. BNP Paribas Financial Markets boosted its holdings in shares of Trevi Therapeutics by 130.9% in the 3rd quarter. BNP Paribas Financial Markets now owns 11,930 shares of the company’s stock valued at $40,000 after acquiring an additional 6,764 shares during the last quarter. Finally, Acuta Capital Partners LLC boosted its holdings in shares of Trevi Therapeutics by 11.7% in the 3rd quarter. Acuta Capital Partners LLC now owns 290,500 shares of the company’s stock valued at $970,000 after acquiring an additional 30,500 shares during the last quarter. 95.76% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Trevi Therapeutics news, insider Farrell Simon sold 81,313 shares of the business’s stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $6.75, for a total transaction of $548,862.75. Following the sale, the insider now owns 76,900 shares of the company’s stock, valued at approximately $519,075. The trade was a 51.39 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 24.37% of the stock is owned by insiders.

About Trevi Therapeutics

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.